Tear trough filler vs PRF EZ Gel: which approach fits which patient.

The under-eye area is one of the most common aesthetic concerns and one of the most difficult to treat. Tear trough hollows, dark circles, and skin crepiness make people look tired regardless of how much sleep they get. Two treatments dominate the conversation: hyaluronic acid tear trough filler and platelet-rich fibrin (PRF) EZ Gel.

They are not interchangeable. HA filler is a structural volumizer that produces immediate correction. PRF EZ Gel is an autologous regenerative treatment that improves skin quality and provides subtle volume over time. Choosing between them — or combining them — depends on what is actually causing the under-eye concern: volume loss, skin quality, pigmentation, or a combination.

Both are injected into one of the most anatomically dangerous areas of the face. The vascular anatomy around the eye connects directly to the ophthalmic artery, and intravascular injection in this zone can cause blindness. The stakes of under-eye injection are higher than almost any other facial site, and the choice of injector matters as much as the choice of product.

What causes under-eye hollows and dark circles

Effective treatment starts with accurate diagnosis. The four primary mechanisms are:

1. Volume loss (fat pad atrophy). The infraorbital fat pads that provide youthful fullness under the eye shrink with age, creating a visible depression — the tear trough. The shadow cast by this depression is the most common cause of the "dark circle" appearance. This is the mechanism that filler addresses most directly.

2. Skin quality (thin skin, crepiness). The skin of the lower eyelid is among the thinnest on the body — approximately 0.5 mm. As collagen and elastin decline with age, the skin becomes thinner, more translucent, and more prone to wrinkling. Thin skin allows underlying vessels and muscle to show through, contributing to a bluish or reddish discoloration. This is the mechanism that PRF EZ Gel addresses most directly.

3. Pigmentation. True hyperpigmentation (melanin deposition in the skin) causes brown-dark circles. This is common in Fitzpatrick III–VI skin types and is worsened by sun exposure and chronic inflammation. Neither filler nor PRF directly targets melanin — this requires topical agents (tranexamic acid, azelaic acid, hydroquinone), chemical peels, or pigment-targeting lasers.

4. Pseudoherniation of orbital fat (eye bags). When the orbital septum weakens, the orbital fat pads bulge forward, creating visible bags. This is a structural problem that filler can paradoxically worsen (by adding volume on top of already protruding fat) and that PRF will not correct. Surgical blepharoplasty is the definitive treatment.

Many patients have a combination of these mechanisms. The treatment plan should address the dominant cause first.

HA tear trough filler: mechanism, products, and technique

Hyaluronic acid fillers work by physically occupying space and attracting water. Injected into the tear trough, they fill the depression between the lower eyelid and the cheek, smoothing the contour and reducing shadowing.

Commonly used products:

• Restylane Eyelight — FDA-approved specifically for under-eye hollows (2023). Uses NASHA Technology for natural-looking integration. The first and only HA filler formulated with NASHA Technology for volume loss under the eyes, though off-label use of other products remains common.
• Juvéderm Volbella XC — Vycross technology, low HA concentration, designed for superficial placement and lips. Low hydrophilicity and smooth texture make it a common tear trough choice. FDA-approved for lips and perioral area.
• Restylane-L — NASHA technology, smaller particle size, lower lifting capacity, smoother integration. Often used for the delicate under-eye skin.
• Belotero Balance — cohesive polydensified matrix, designed for superficial to mid-dermis integration. Low Tyndall effect risk.

Except for Eyelight, these products do not carry an FDA-approved indication specifically for tear trough correction. Off-label use is standard in aesthetic medicine but should be disclosed to the patient.

Technique considerations:

• Placement should be deep (supraperiosteal or deep within the suborbicularis oculi fat) rather than superficial. Superficial placement increases the risk of the Tyndall effect and visible lumps.
• Cannulas are generally preferred over needles for under-eye injection, as they reduce the risk of intravascular injection and allow smoother product distribution.
• Small volumes are essential. The tear trough typically requires 0.3–0.5 mL per side. Over-injection is the most common error and leads to puffiness, visible product, and a worsened appearance.
• Ultrasound guidance is increasingly recommended for high-risk periocular injections to visualize vessels and confirm filler placement.

Results: Immediate visible correction. Full settling at approximately 2 weeks. Duration: 6–18 months depending on product, volume, and individual metabolism.

PRF EZ Gel: mechanism, preparation, and technique

Platelet-rich fibrin (PRF) is a second-generation autologous platelet concentrate. It is derived entirely from the patient's own blood, prepared without anticoagulants, using low-speed centrifugation. The result is a fibrin matrix rich in platelets, leukocytes, and growth factors (PDGF, TGF-β, VEGF, IGF-1).

PRF EZ Gel is a processed form of PRF that undergoes a controlled heating and cooling cycle to create a more viscous, gel-like consistency. This provides:

• Better structural integrity for injection (closer to a filler-like consistency than liquid PRF)
• Slower resorption (the gel matrix releases growth factors over a longer period)
• Easier injection through a cannula

How it works under the eyes:

• The gel matrix provides an initial volumizing effect that partially fills the tear trough and reduces shadowing.
• Over the following weeks, the concentrated growth factors stimulate fibroblast activity, collagen production, and angiogenesis.
• The regenerative process improves skin thickness, tone, and elasticity — addressing the thin-skin component that filler cannot fix.
• Because EZ Gel is entirely autologous (derived from the patient's own blood), there is no risk of allergic reaction to synthetic material, no Tyndall effect, and no risk of foreign-body granuloma.

Technique:

• A blood draw is required (typically 1–2 tubes).
• The blood is centrifuged at low speed to separate the PRF.
• The PRF is heated and cooled to create the gel matrix.
• The gel is injected using a blunt-tipped cannula into the tear trough area.

Results: Gradual improvement over 4–12 weeks. Initial volume from the gel matrix diminishes as the fibrin is resorbed, but the collagen-building effects continue to improve skin quality for months. A series of 3 treatments spaced 4–6 weeks apart is standard. Maintenance treatments every 6–12 months.

Direct comparison

The vascular anatomy problem

Both HA filler and PRF EZ Gel are injected into the tear trough, which sits in a vascular danger zone. The area between a line crossing the medial pupil and the lateral wall of the nose is described as particularly high-risk due to anastomoses between the nasal branch of the infraorbital artery and the supratrochlear, dorsal nasal, and angular arteries — all of which connect to the ophthalmic artery.

The FDA has documented the mechanism clearly: inadvertent penetration of an artery in the face with a needle or cannula, followed by intra-arterial injection under pressure, can carry filler retrograde through the ophthalmic artery to the central retinal artery, causing blindness. Further embolization can reach the internal carotid artery, causing stroke.

Key data points from the FDA and published literature:

• The most common injection sites associated with vision loss are the nose (~41%), forehead (~28%), and glabella (~19%), per a 2024 comprehensive review of over 500 published cases (Doyon et al., Aesthetic Surgery Journal). The tear trough is less commonly implicated but documented.
• Among patients with filler-associated ophthalmic artery occlusion, approximately 68% had no vision recovery despite intervention.
• Approximately 19% of cases had concurrent intracranial embolic events.
• HA filler was the most frequently implicated material (~80% of published cases).

This does not mean under-eye injection is unreasonably dangerous. It means that the injector's expertise in facial vascular anatomy, injection technique (cannula vs. needle, slow injection, aspiration), and emergency preparedness (hyaluronidase on-site, emergency protocols) are non-negotiable. The choice between filler and PRF EZ Gel does not eliminate this risk — any injectable in this area carries it.

Which patients fit which treatment

HA filler is the better fit when:

• The dominant problem is volume loss (deep tear trough hollowing with clear shadowing)
• The patient wants immediate, visible correction
• The skin quality is reasonable (not severely thin or crepey)
• The patient understands and accepts the risks of HA filler in this area
• The injector is experienced in periocular injection with cannula technique

PRF EZ Gel is the better fit when:

• The dominant problem is skin quality (thin skin, crepiness, fine lines, visible vessels)
• The tear trough hollowing is mild to moderate
• The patient prefers an autologous, non-synthetic approach
• The patient is willing to commit to a series of treatments and wait for gradual improvement
• The patient has had previous adverse reactions to HA filler (swelling, Tyndall effect)

Neither is the right fit when:

• The primary issue is true orbital fat herniation (eye bags) — surgical consultation is more appropriate
• The primary issue is hyperpigmentation — topical or pigment-targeting laser treatment is more appropriate
• The patient has active inflammatory skin conditions around the eyes
• The patient has a history of severe allergic reactions and the injector does not have emergency equipment on-site
• The patient expects correction of significant facial aging with under-eye treatment alone

Combined approaches are common. Many experienced injectors use PRF EZ Gel as a first-line skin-quality treatment, followed by judicious micro-doses of HA filler for residual volume deficit. The sequence matters: PRF first improves the tissue bed, and filler placed later integrates more smoothly.

Questions to ask at your consultation

1. What is the primary cause of my under-eye concern — volume loss, skin quality, pigmentation, or fat herniation?
2. What is your experience specifically with under-eye injection? How many tear trough treatments do you perform per month?
3. Do you use cannulas for under-eye injection?
4. Do you have ultrasound available for vessel mapping and injection guidance?
5. Do you have hyaluronidase on-site and a protocol for vascular emergencies?
6. What product do you recommend, and why this one over alternatives?
7. If I choose PRF EZ Gel, how many sessions do you typically recommend, and what is the total cost?
8. If I choose filler and I do not like the result, can it be reversed?

Sources

• FDA Summary of Safety and Effectiveness Data (SSED) for Restylane Eyelight (P040024/S135). https://www.accessdata.fda.gov/cdrh_docs/pdf4/P040024S135B.pdf
• FDA Executive Summary: General Issues Panel Meeting on Dermal Fillers. https://www.fda.gov/media/188185/download
• Doyon L, et al. Worldwide occurrence of vision loss and other ocular complications following soft-tissue filler injection: a comprehensive review and update. Aesthet Surg J. 2024. https://pubmed.ncbi.nlm.nih.gov/38268990/
• Complications of periorbital cosmetic hyaluronic acid filler injections: a major review. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12559836/
• Intravascular injection of soft-tissue fillers can have severe visual consequences. AAO. https://www.aao.org/education/editors-choice/intravascular-injection-of-soft-tissue-fillers-can
• Preventing and treating blindness from dermal fillers. Nursing CE. https://nursing.ceconnection.com/files/PreventingandTreatingBlindnessFromDermalFillers-1753189925663.pdf
• FDA assessing and monitoring for intravascular injections. https://www.fda.gov/media/147034/download
• The 5 key risks of under-eye filler injections. Moorfields Private. https://moorfields.nhs.uk/private/about-moorfields-private/blog-articles/the-5-key-risks-of-under-eye-filler-injections
• PRF EZ Gel under eye for transforming tear trough results. HubMed Ed. https://www.hubmeded.com/blog/prf-ez-gel-under-eye-rejuvenation
• PRF under eyes: a critical consideration of benefits. Selphyl. https://www.selphyl.com/post/prf-under-eyes-a-critical-consideration-of-benefits
• PRF EZ Gel for under eyes: treat dark circles naturally. Allen Medical Aesthetics. https://allenmedicalaesthetics.com/blog/prf-ez-gel-under-eye
• Preventing and treating adverse events of injectable fillers: evidence-based recommendations from ASDS task force. ASDS. https://www.asds.net/Portals/0/PDF/asdsa/Preventing%20and%20Treating%20Adverse%20Events%20of%20Injectable%20Fillers%20Evidence-Based%20Recs%20From%20ASDS%20Task%20Force%20Article.pdf